We are delighted to introduce the EmpAItica project, a ground-breaking initiative to support people with depression. This ambitious endeavor brings together experts from industry and research to develop an innovative solution to one of the most pressing problems in mental health care: the lack of fast and accessible help. According to the World Health Organization's report, over 300 million people worldwide live with depression, representing 5% of the global population. According to reports from the German Depression Aid Foundation, the 12-month prevalence in Germany is around six million.
Europe's first MDR Iia certified conversational agent
EmpAItica is an AI-based conversational agent that has been specially developed to detect depression and support those affected. The aim of the funding project is to certify the module in accordance with MDR IIa. This would be the first LLM-based conversational agent in Europe that can be used in a medical environment. Using a multimodal approach - based on speech, facial expressions and gestures - the chatbot can analyze emotional states in real time and respond sensitively to the user's needs. The aim is to build a bridge to professional help for those affected while they wait for a place in therapy.
Integration into digital healthcare
The EmpAItica module will be integrated directly into our existing medical platform, which is already being used successfully in medical facilities. The platform enables telemedical monitoring and the collection of important health data. This expansion will create a holistic approach to mental healthcare. We see particular potential in nursing homes or assisted living facilities.
Key features of the module:
Empathic communication: the conversational agent conducts semi-clinical interviews, recognizing emotional states with high precision.
Multimodal recognition: The AI analyzes text, audio and video data to identify signs of depression.
User-centered help: Those affected receive recommendations for action and support without replacing the role of therapists.
MDR IIa certification: This means that the conversational agent can be used for medical purposes.
Research and development partners
The project combines the expertise of Actimi GmbH, Radloff Clinical Consulting and Reutlingen University. It is supported by other partners such as PFH Göttingen and Soulfi GmbH. The collaboration enables the development of a certified medical device that meets the highest regulatory requirements.
Looking to the future
EmpAItica lays the foundation for a new generation of digital healthcare solutions. The project will not only improve the early detection of depression, but also strengthen Baden-Württemberg's position as a pioneer in the field of digital health. With a clear focus on innovation and ethical AI development, EmpAItica demonstrates how technology can sustainably improve healthcare.
We would like to thank all partners and funding institutions for the successful collaboration and look forward to future projects that will further advance digital healthcare.
We are delighted to introduce the EmpAItica project, a ground-breaking initiative to support people with depression. This ambitious endeavor brings together experts from industry and research to develop an innovative solution to one of the most pressing problems in mental health care: the lack of fast and accessible help. According to the World Health Organization's report, over 300 million people worldwide live with depression, representing 5% of the global population. According to reports from the German Depression Aid Foundation, the 12-month prevalence in Germany is around six million.
Europe's first MDR Iia certified conversational agent
EmpAItica is an AI-based conversational agent that has been specially developed to detect depression and support those affected. The aim of the funding project is to certify the module in accordance with MDR IIa. This would be the first LLM-based conversational agent in Europe that can be used in a medical environment. Using a multimodal approach - based on speech, facial expressions and gestures - the chatbot can analyze emotional states in real time and respond sensitively to the user's needs. The aim is to build a bridge to professional help for those affected while they wait for a place in therapy.
Integration into digital healthcare
The EmpAItica module will be integrated directly into our existing medical platform, which is already being used successfully in medical facilities. The platform enables telemedical monitoring and the collection of important health data. This expansion will create a holistic approach to mental healthcare. We see particular potential in nursing homes or assisted living facilities.
Key features of the module:
Empathic communication: the conversational agent conducts semi-clinical interviews, recognizing emotional states with high precision.
Multimodal recognition: The AI analyzes text, audio and video data to identify signs of depression.
User-centered help: Those affected receive recommendations for action and support without replacing the role of therapists.
MDR IIa certification: This means that the conversational agent can be used for medical purposes.
Research and development partners
The project combines the expertise of Actimi GmbH, Radloff Clinical Consulting and Reutlingen University. It is supported by other partners such as PFH Göttingen and Soulfi GmbH. The collaboration enables the development of a certified medical device that meets the highest regulatory requirements.
Looking to the future
EmpAItica lays the foundation for a new generation of digital healthcare solutions. The project will not only improve the early detection of depression, but also strengthen Baden-Württemberg's position as a pioneer in the field of digital health. With a clear focus on innovation and ethical AI development, EmpAItica demonstrates how technology can sustainably improve healthcare.
We would like to thank all partners and funding institutions for the successful collaboration and look forward to future projects that will further advance digital healthcare.
We are delighted to introduce the EmpAItica project, a ground-breaking initiative to support people with depression. This ambitious endeavor brings together experts from industry and research to develop an innovative solution to one of the most pressing problems in mental health care: the lack of fast and accessible help. According to the World Health Organization's report, over 300 million people worldwide live with depression, representing 5% of the global population. According to reports from the German Depression Aid Foundation, the 12-month prevalence in Germany is around six million.
Europe's first MDR Iia certified conversational agent
EmpAItica is an AI-based conversational agent that has been specially developed to detect depression and support those affected. The aim of the funding project is to certify the module in accordance with MDR IIa. This would be the first LLM-based conversational agent in Europe that can be used in a medical environment. Using a multimodal approach - based on speech, facial expressions and gestures - the chatbot can analyze emotional states in real time and respond sensitively to the user's needs. The aim is to build a bridge to professional help for those affected while they wait for a place in therapy.
Integration into digital healthcare
The EmpAItica module will be integrated directly into our existing medical platform, which is already being used successfully in medical facilities. The platform enables telemedical monitoring and the collection of important health data. This expansion will create a holistic approach to mental healthcare. We see particular potential in nursing homes or assisted living facilities.
Key features of the module:
Empathic communication: the conversational agent conducts semi-clinical interviews, recognizing emotional states with high precision.
Multimodal recognition: The AI analyzes text, audio and video data to identify signs of depression.
User-centered help: Those affected receive recommendations for action and support without replacing the role of therapists.
MDR IIa certification: This means that the conversational agent can be used for medical purposes.
Research and development partners
The project combines the expertise of Actimi GmbH, Radloff Clinical Consulting and Reutlingen University. It is supported by other partners such as PFH Göttingen and Soulfi GmbH. The collaboration enables the development of a certified medical device that meets the highest regulatory requirements.
Looking to the future
EmpAItica lays the foundation for a new generation of digital healthcare solutions. The project will not only improve the early detection of depression, but also strengthen Baden-Württemberg's position as a pioneer in the field of digital health. With a clear focus on innovation and ethical AI development, EmpAItica demonstrates how technology can sustainably improve healthcare.
We would like to thank all partners and funding institutions for the successful collaboration and look forward to future projects that will further advance digital healthcare.
